Patients should be wary of unregulated online pharmacies or suppliers offering Mounjaro without proper clinical oversight, as this poses significant safety risks
Two pillars met (clinical protocol, follow-up cadence)
Mole darkening and documented melanoma risk
1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization

Wegovi (semaglutide) BMI Requirements Most telemedicine platforms that offer GLP-1's for medical Weight Loss follow a strict guideline as far as BMI is concerned to qualify for semaglutide or tirzepatide (active ingredients in Wegovy and Zepbound)
*These statements have not been evaluated by the FDA and are not intended to treat or cure any disease